| 股票简称 | 股票代码 | 限售股类型 | 解禁股数 | | --- | --- | --- | --- | | 弘业期货 | 001236 | 发行前股份限售流通 | 4.32亿 | | 江波龙 | 301308 | 发行前股份限售流通 | 3亿 | | 广立微 | 301095 | 发行前股份限售流通 | 7592.2万 | | 中微半导 | 688380 | | 2128.5万 | | 盟科药业 | 688373 | | 2.83亿 | 今日具体限售解禁股情况如下： 智通财经APP获悉，8月5日共有5家上市公司的限售股解禁，解禁总市值约382.85亿元。 ...

Core Viewpoint - The company plans to utilize temporarily idle raised funds for cash management, with a maximum amount of RMB 400 million, to enhance the efficiency of fund usage and increase returns for the company and its shareholders [4][12][18] Summary by Sections 1. Basic Situation of Raised Funds - The company was approved to publicly issue 63 million shares at a price of RMB 30.86 per share, raising a total of RMB 1,944.18 million, with a net amount of RMB 1,816.50 million after deducting fees [1][2] 2. Previous Use of Idle Funds - In August 2024, the company approved the use of up to RMB 950 million of temporarily idle raised funds for cash management, ensuring that it would not affect the implementation of investment projects [2][3] 3. Current Cash Management Plan - The company intends to use a maximum of RMB 400 million of temporarily idle raised funds for cash management, with a validity period of 12 months from the board's approval date [4][8] 4. Purpose of Cash Management - The aim is to improve the efficiency of fund usage while ensuring the safety of the raised funds and not affecting the construction of investment projects [4][18] 5. Investment Products - The company will invest in high-security, high-liquidity products with capital protection agreements, including but not limited to structured deposits, time deposits, and large certificates of deposit [6][7] 6. Management and Oversight - The board authorizes the management to make investment decisions within the approved limits, with the finance department responsible for implementation [9][12] 7. Monitoring and Compliance - The company will adhere to relevant regulations and ensure proper disclosure of information regarding the management of raised funds [10][14]

据公开信息，中微半导于7月首次披露拟赴港IPO计划，成为当月17家公告赴港上市的A股公司之一。这 一动态显示公司正推进国际化资本布局，但具体时间表及募资规模尚未公布。 截至2025年8月4日收盘，中微半导股价报28.41元，较前一交易日上涨1.21%，成交额达1.42亿元。当日 主力资金净流出1904.07万元，近五日累计净流出4539.90万元。 中微半导主营业务为半导体芯片设计，产品覆盖消费电子、工业控制等领域。公司所属板块包括半导 体、汽车芯片及传感器等产业链。 本文源自：金融界 作者：A股君 风险提示：市场有风险，投资需谨慎。 ...

Group 1 - The company plans to use up to RMB 400 million of temporarily idle raised funds for cash management [1] - The usage period for the funds is effective for 12 months from the date of approval by the company's board of directors [1] - The funds can be used in a rolling manner within the specified limit and time frame [1]

Group 1 - The company plans to use up to RMB 400 million of temporarily idle raised funds for cash management [1] - The usage period for the funds is effective for 12 months from the date of approval by the company's board of directors [1] - The funds can be used in a rolling manner within the specified limit and time frame [1]

中信证券股份有限公司 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为中微半 导体（深圳）股份有限公司（以下简称"公司"、"中微半导"或"发行人"）首 次公开发行股票并在科创板上市的保荐人。根据《证券发行上市保荐业务管理办 法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》等有关规定，对公司使用暂时闲置募集资金进 行现金管理的事项进行了核查，核查情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意中微半导体（深圳）股份有限公司 首次公开发行股票注册的批复》（证监许可〔2022〕910 号），同意公司首次公开 发行股票的注册申请。公司获准向社会公开发行人民币普通股 63,000,000 股，每 股发行价格为 30.86 元，募集资金总额为 194,418.00 万元，扣除承销及保荐费用、 发行登记费以及其他交易费用共计 12,767.91 万元（不含增值税金额），募集资金 净额为 181,650.09 万元，上述资金已全部到位。经天健会计师事务所（特殊普通 合伙）对公司本次公开发行新股的资金到位情况进行了审验，并于 2022 ...

证券代码：688380 证券简称：中微半导 公告编号：2025-026 中微半导体（深圳）股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中微半导体（深圳）股份有限公司（以下简称"公司"）于2025年8月1日召开第 二届董事会第二十五次会议和第二届监事会第二十二次会议，审议通过了《关于使 用暂时闲置募集资金进行现金管理的议案》，同意公司使用额度不超过人民币4.0亿 元（含本数）的暂时闲置募集资金进行现金管理，用于购买安全性高、流动性好、有 保本约定的投资产品（包括但不限于协定存款、结构性存款、定期存款、通知存款 、大额存单、收益凭证等），使用期限自公司董事会审议通过之日起12个月内有效 。在上述额度及期限范围内，资金可以循环滚动使用，董事会授权公司管理层在授 权额度和期限内行使现金管理投资决策权并签署相关文件，具体事项由公司财务部 负责组织实施。具体内容如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意中微半导体（深圳）股份有限公司首次 公开发行股票注册 ...

Group 1 - The core point of the announcement is the renewal of the "Consistent Action Agreement" among the major shareholders of the company, which aims to ensure stable control and decision-making efficiency for the company's future development [1][2][4] Group 2 - The background of the renewal indicates that the original agreement was signed on December 25, 2019, and was set to expire on August 4, 2025. The agreement mandates that shareholders Zhou Yan and Zhou Fei must align their voting with Yang Yong's decisions [1][2] - The main content of the renewed agreement specifies that the consistent action period will now extend from August 5, 2025, to August 4, 2027, maintaining the requirement for unified voting [3] - The impact of the renewal confirms that there is no change in the company's controlling shareholders or actual controllers, which remains Yang Yong, Zhou Yan, and Zhou Fei. This stability is expected to benefit the company's strategic development and management policies [4]

Monetary Policy and Financial Support - The central bank will continue to implement a moderately loose monetary policy and promote rapid growth in loans to technology-oriented small and medium-sized enterprises, increasing financing support for key areas such as "two new" and "two heavy" [1] Taxation Changes - Starting from August 8, 2025, the Ministry of Finance and the State Taxation Administration will reinstate value-added tax on interest income from newly issued national bonds, local government bonds, and financial bonds [2] Infrastructure Development - Shanghai aims to establish at least five large-scale computing centers by the end of 2025, with a target computing power scale of over 100 EFLOPS (FP16) [3] Pharmaceutical Industry Insights - The Anhui Province centralized procurement platform has initiated market information collection for biological agents. Experts believe that the collective procurement of biological drugs cannot be directly compared to that of generic drugs, indicating significant flexibility in the pace of advancement and future price reductions [4] Company Performance - Shihua Machinery's independent director Zhou Jingping is under investigation [5] - Hikvision reported a year-on-year net profit increase of 11.71% in the first half of the year [5] - Ninebot Company achieved a net profit of 1.242 billion yuan in the first half of the year, a year-on-year increase of 108% [5] - BYD's automobile sales in July reached 344,296 units, a month-on-month decrease of 8.8% [5] - Luzhou Laojiao announced a dividend of 45.92 yuan per 10 shares for the 2024 fiscal year [5] - InnoCare responded to its collaboration with NVIDIA, stating that it is in the testing phase with no substantial orders yet [5]

近日，中微半导体（深圳）股份有限公司（以下简称"公司"）收到公司实 际控制人、控股股东杨勇、周彦、周飞续签《一致行动人协议》的通知，具体情 况如下： 一、本次续签《一致行动人协议》的背景情况 杨勇、周彦、周飞均为公司股东。杨勇、周彦别为公司第一、第二大股东， 周飞为周彦的弟弟。2019年 12 月 25 日，上述三人签署了《一致行动人协议》， 约定各方对于须由公司股东大会审议的事项，周彦、周飞应遵照杨勇的表决意见 行使股东表决权，即周彦、周飞应无条件确保其表决意见与杨勇保持一致，并约 定该《一致行动人协议》有效期自签订之日起至公司首次公开发行股票并合格 上市届满三年之日止。 证券代码：688380 证券简称：中微半导 公告编号：2025-025 中微半导体（深圳）股份有限公司 关于实际控制人续签一致行动人协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 中微半导体（深圳）股份有限公司董事会 2025 年 8 月 2 日 2 截至本公告披露日，杨勇、周彦、周飞分别持有公司股份数量 126,000,000 股、91, ...